iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Sun Pharma Advanced dives 5% after Parkinson's drug trial halted

10 Apr 2024 , 11:18 AM

On April 10, Sun Pharma Advanced Research Company (SPARC) shares dropped 5% to reach the lower circuit following the Mumbai-based pharmaceutical company’s announcement that it was giving up on its Phase 2 study of Vodobatinib for Parkinson’s disease.

A global trial called PROSEEK included 513 individuals from India, Europe, and the United States who had early-stage Parkinson’s disease. The selective c-Abl tyrosine kinase inhibitor was intended to be tested for safety and effectiveness in individuals with early-stage Parkinson’s disease.

The Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III was used to quantify symptoms, and the study’s main objective was to demonstrate a decrease in those symptoms.

Sun Pharma Advanced Research Company stated that the interim analysis, which was based on data from 442 patients who finished their 40 weeks of treatment, did not show that vodobatinib was superior to a placebo in the primary endpoint.

“SPARC has reviewed the data and determined that the study has not shown evidence of treatment benefit in patients receiving Vodobatinib, and consequently decided to close the study,” the business stated to exchanges. In the upcoming months, it intends to finish the comprehensive examination of the correlated biomarker data and clinical outcomes.

On the National Stock Exchange (NSE), SPARC shares were trapped in a 5% downward circuit at Rs 429.70 at 10:12 a.m. The stock has increased by almost 40% so far this year, outpacing the benchmark Nifty 50’s 4% gain during the same period. Over the past year, SPARC has produced returns of more than 134%.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Parkinson's
  • SPARC
  • Sun Pharma Advanced Research Company
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.